Trials / Completed
CompletedNCT03426631
DAW1033B2 in Obstructive Sleep Apnea
Effect of DAW1033B2 on Obstructive Sleep Apnea
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033B2 administered before sleep on OSA phenotype traits and OSA severity during sleep.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo oral capsule | Placebo capsule 30 minutes before sleep |
| DRUG | DAW1033B2 oral capsule | DAW1033B2 capsule 30 minutes before sleep |
Timeline
- Start date
- 2017-09-15
- Primary completion
- 2019-10-01
- Completion
- 2020-01-20
- First posted
- 2018-02-08
- Last updated
- 2020-02-19
- Results posted
- 2020-02-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03426631. Inclusion in this directory is not an endorsement.